Product Information Sheet for MRA-155G

Genomic DNA from *Plasmodium falciparum*, Strain HB3

Catalog No. MRA-155G

This reagent is the tangible property of the U.S. Government.

For research use only. Not for use in humans.

Contributor:

Thomas E. Wellems, M.D., Ph.D., Chief, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA

Manufacturer:

BEI Resources

Product Description:

Genomic DNA was extracted from a preparation of *Plasmodium falciparum (P. falciparum)*, strain HB3.

P. falciparum, strain HB3 was cloned from the Honduras I/CDC strain, originally isolated from a patient in Honduras during an outbreak of urban malaria in 1980.[1,2,3] *P. falciparum*, strain HB3 is a chloroquine-sensitive parent strain of two published *P. falciparum* genetic crosses, between parasite strains 3D7 × HB3 and HB3 × Dd2.[4,5] The complete genome of *P. falciparum*, strain HB3 has been sequenced (GenBank: AANS00000000).

MRA-155G has been qualified for PCR applications by amplification of approximately 900 base pairs of the merozoite surface protein 2 (MSP2) gene.

Material Provided:

Each vial of MRA-155G contains approximately 0.5 µg of genomic DNA in buffer. The amount per vial, concentration and buffer composition are shown on the Certificate of Analysis. The vial should be centrifuged prior to opening.

Packaging/Storage:

MRA-155G was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen on dry ice and should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be minimized.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Genomic DNA from *Plasmodium falciparum*, Strain HB3, MRA-155G, contributed by Thomas E. Wellems."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 6th ed. Washington, DC: U.S. Government Printing Office, 2020; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Bhasin, V. K. and W. Trager. "Gametocyte-Forming and Non-Gametocyte-Forming Clones of *Plasmodium falciparum*." Am. J. Trop. Med. Hyg. 33 (1984): 534-537. PubMed: 6383092.
2. Wellems, T. E., Personal Communication.
3. Nguyen-Dinh, P. and D. Payne. "Pyrimethamine Sensitivity in *Plasmodium falciparum*: Determination *in vitro* by a Modified 48-Hour Test." Bull. World Health Organ. 58 (1980): 909-912. PubMed: 7011588.
4. Walliker, D., et al. "Genetic Analysis of the Human Malaria Parasite *Plasmodium falciparum*." Science 236 (1987): 1661-1666. PubMed: 3299700.
5. Su, X.-Z., et al. "A Genetic Map and Recombination Parameters of the Human Malaria Parasite *Plasmodium falciparum*." Science 286 (1999): 1351-1353. PubMed: 10558988.

BEI Resources
www.beiresources.org

E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898